By: IPP Bureau
Last updated : November 21, 2025 11:17 am
The licence covers Actimed’s existing patents, its proprietary know-how and any future related patents, giving Mankind full control to advance the products under its own brands
Actimed has partnered with Mankind Pharma to bring its cachexia treatment, including the lead asset S-pindolol benzoate, to India and other South Asian markets through a licensing agreement. This collaboration will help fund the development of the treatment and make it available to patients in the region.
The agreement hands Mankind exclusive rights to develop, manufacture and commercialise Actimed’s cachexia-focused products across the Indian subcontinent.
The licence covers Actimed’s existing patents, its proprietary know-how and any future related patents, giving Mankind full control to advance the products under its own brands.
The partnership confines Mankind’s rights to the treatment and prevention of cachexia, a debilitating condition with few effective therapies. Mankind will shoulder all development, manufacturing and commercial costs as it prepares to bring the therapies to one of the world’s most populous regions.
Atish Majumdar, Senior President (Sales & Marketing) at Mankind Pharma and a non-executive director at Actimed, said the deal deepens a long-standing relationship.
“This collaboration reflects our shared commitment to advancing innovative therapies and improving the lives of patients affected by cachexia across the Indian subcontinent,” he said. “We have strong confidence in Actimed’s vision, leadership and development expertise.”
Actimed CEO Robin Bhattacherjee called the agreement a major step toward addressing a condition with no globally approved treatments. “By combining the Actimed cachexia pipeline with Mankind’s strong development and commercial capabilities, we are moving closer to delivering meaningful treatment options to cachexia patients globally,” he said.